Navigation Links
Actavis Launches Amlodipine Tablets in the U.S.
Date:9/7/2007

MORRISTOWN, N.J., Sept. 7 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received final approval of amlodipine besylate tablets from the U.S. Food & Drug Administration. Distribution of the product will commence immediately.

Amlodipine besylate tablets, the generic equivalent of Pfizer's Norvasc(R) tablets, will be available in 2.5 mg, 5 mg and 10 mg strengths and are indicated for the treatment of hypertension, chronic stable angina and vasospastic angina.

Annual sales of amlodipine besylate tablets in the U.S. were approximately US$2.5 billion for the twelve months ending June 2007 according to IMS Health data.

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 39 countries, with 11,000 employees. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market. In the U.S. alone, the company made 38 ANDA filings in 2006 and expects to file 40-45 in the year 2007 along with 18-20 new product launches. The company's U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by thes
'/>"/>

SOURCE Actavis Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. Dr Reddy’s Laboratories launches Hyalosy
4. Serum Institute Launches New Tetanus-Diphtheria Vaccine
5. Scottish Health Minister Launches Organ Donor Plan
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Pfizer Launches Viagra For Lung Disease In UK
8. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
9. PM Launches Healthcare Foundation For India
10. African Union Launches A Programme On Acceleration of HIV Prevention
11. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars ... 7788 East Horn Road in Lake Leelanau. Joining the Northern ... Cellars is the 25th winery along the trail. The winery ... tour events, making its trail event debut during the Harvest ... Owners David and Faye Mathia opened the boutique winery in ...
(Date:7/31/2014)... July 31, 2014 Ce-Classes.com has announced ... course for healthcare professionals, a Systematic Review of ... material published in the International Journal of Clinical and ... in response to a need to have accurate information ... the best treatment possible. The material provides a ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2
... type of disease, that requires insulin injections daily. Researchers ... this disease. Some medical research centers in the U.S. ... I diabetes by transplanting insulin-producing islet cells combined with ... live normal lives without insulin. , ...
... come up with a new technique of removing cancerous ... their hands and a special camera and instuments. This ... in significantly less time than the standard laproscopic procedure. ... of the American Urological Association by surgeons from the ...
... new gene which has the ability to slow down ... millions of people each year, and luckily tthe discovery ... the cancer of the colon, prostate,pancreas,brain and bowel. ... to stunt the cancer by starving the tumour ...
... from Mayo Clinic brings more choice in eating heath food// ... into any weight loss diets that restrict choices in food. ... the report that talks of sustainable eating habits that help ... weight requires a long-term commitment to making lifestyle changes. However, ...
... Researchers from UCLA had reported in the recent issue ... sleep suffer from loss of brain cells due to ... apnea, the person stops breathing during the sleep when ... in the brain as preB?tzinger complex (preB?tC), which is ...
... and its function has always left man dazzled for ... key factors// have been identified that could answer the ... babies and hence help treat prematurity. ,Identification ... brain damage repair in neurological diseases like multiple sclerosis ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Making operation and recovery time shorter 2Health News:New Healthy Weight Program Makes Healthy Eating More Interesting 2Health News:Sleep Apnea Related To Death And Loss Of Brain Cells 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
(Date:7/31/2014)... , July 31, 2014 Hovione ... Ireland has successfully passed a pre-approval inspection by ... inspection, carried out by the FDA Consumer Safety Officer, Ms. ... started on 21 st July and concluded on the ... compliant with the principles and guidelines of Good Manufacturing Practices ...
(Date:7/31/2014)... 31, 2014 Catylix, Inc. ( ... Milpitas, California ) announced today the ... commercialize new fluorination products and related chemistry. ... from the use of substituents that are chemically ... polarity to improve binding and bioavailability. Fluorinated functional ...
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... in a Single Pill to Target Three Major ... Next Phase of Development, ABBOTT PARK, Ill. and ... will advance the development of,Abbott,s next-generation fenofibrate ABT-335 and ... Phase III,clinical trials. The single pill would target all ...
... Aug. 30 ,Palatin Technologies, Inc. (Amex: PTN ... announced today that they have delayed plans for ... a first in class,melanocortin agonist drug candidate, for ... follows responses from representatives of,the U.S. Food and ...
Cached Medicine Technology:Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 2Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 3King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2
... Final Flexion Wraps restore full PIP joint ... when lost due to arthritic changes. Unparalleled ... material hugs the finger to prevent slipping ... motion. One size. Sold in packages of ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... braces are designed to provide comfortable stabilization ... and versatile, ROM braces are an easy ... The braces are extremely patient-friendly, too. , ... hinges that allow you to restrict extension ...
Medicine Products: